Eisai, Purdue To File Insomnia Drug Following Positive Head-To-Head
Eisai and its partner Purdue are expected to file insomnia drug lemborexant with the US FDA within the next 12 months, following more positive data.
You may also be interested in...
The Japanese pharma, continuing to bolster its pipeline after buying Shire, is partnering with Skyhawk in neurodegenerative diseases under another new deal. Also, Purdue cites shifting business priorities for a decision to end Eisai collaboration on sleep disorder drug.
The latest drug development news and highlights from our US FDA Performance Tracker.
Only the first publicly disclosed sale of a priority review voucher was lower than what Jazz Pharmaceuticals paid Spark Therapeutics for its coupon.